Daniel B. Hall
University of Georgia · 59 works · 4,444 citations · h-index 26
Top works
- Fabrication of single-crystal semiconductor optical waveguides by solid-state diffusion
- High-Dose Nevirapine: Safety, Pharmacokinetics, And Antiviral Effect In Patients With Human Immunodeficiency Virus Infection
- Acute Hepatitis B Virus Infection: Relation of Age to the Clinical Expression of Disease and Subsequent Development of the Carrier State
- Optical waveguides by diffusion in II-VI compounds
- Oxidative DNA damage through long-range electron transfer
- Long-range oxidative damage to DNA: Effects of distance and sequence
- High‐Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1‐Infected Persons Does Not Result in Sustained Suppression of Viral Replication
- The Long-Term Serological Course of Asymptomatic Hepatitis B Virus Carriers and the Development of Primary Hepatocellular Carcinoma
- Alternating Nevirapine and Zidovudine Treatment of Human Immunodeficiency Virus Type 1-Infected Persons Does Not Prolong Nevirapine Activity
- Leaky waves in a heteroepitaxial film
- Invasive Haemophilus influenzae Type b Disease in Alaska: Background Epidemiology for a Vaccine Efficacy Trial
- Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children
- Risk Factors for Crimean-Congo Hemorrhagic Fever in Rural Northern Senegal
- Sensitivity of DNA-Mediated Electron Transfer to the Intervening π-Stack: A Probe for the Integrity of the DNA Base Stack
- The transcription factor Ifh1 is a key regulator of yeast ribosomal protein genes
- Confinement and processing effects on glass transition temperature and physical aging in ultrathin polymer films: Novel fluorescence measurements
- New triborate-pillared hydrotalcites
- Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy
- The VP16 Activation Domain Interacts with Multiple Transcriptional Components as Determined by Protein-Protein Cross-linking in Vivo
- OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn’s disease patients from the open-label extension study